Provided by Tiger Trade Technology Pte. Ltd.

Lixte Biotechnology Holdings Inc.

2.89
-0.0200-0.69%
Post-market: 2.890.00000.00%18:04 EST
Volume:36.23K
Turnover:104.72K
Market Cap:25.15M
PE:-2.39
High:2.97
Open:2.96
Low:2.76
Close:2.91
52wk High:6.26
52wk Low:0.6400
Shares:8.70M
Float Shares:7.99M
Volume Ratio:1.20
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2110
EPS(LYR):-1.5943
ROE:-130.06%
ROA:-68.32%
PB:10.66
PE(LYR):-1.81

Loading ...

Lixte Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment

THOMSON REUTERS
·
Nov 25, 2025

Lixte Biotechnology Holdings Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Oct 17, 2025

Lixte Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate Lb-100, Strategic Oncology Business Development and Acquisition Plans

THOMSON REUTERS
·
Oct 16, 2025

Lixte Biotechnology Holdings Inc. Announces Leadership Reshuffle with Geordan Pursglove as CEO and Bas van der Baan as Chief Scientific Officer

Reuters
·
Sep 16, 2025

Lixte Biotechnology Invests $2.6M in Cryptocurrencies

TIPRANKS
·
Sep 12, 2025

Lixte Biotechnology purchases 10.5 Bitcoin, 300 Ethereum for $2.6M

TIPRANKS
·
Sep 11, 2025

Lixte Biotechnology Holdings Inc - Purchases 10.5 Bitcoin and 300 Ethereum for $2.6 Mln

THOMSON REUTERS
·
Sep 11, 2025

Lixte Biotechnology Holdings Inc. Files Initial Beneficial Ownership Statement for Director Guy Primus

Reuters
·
Sep 11, 2025

Lixte Biotechnology Holdings Inc. Announces Breakthrough Clinical Trial for LB-100, the World's Only Clinical-Stage PP2A Inhibitor, Targeting Cancer Treatment Synergies

Reuters
·
Sep 05, 2025

Lixte Biotechnology Holdings Inc. Files Initial Statement of Beneficial Ownership for Director Felix Lourdes

Reuters
·
Sep 05, 2025

BRIEF-Lixte Biotechnology Holdings Inc - Peter Stazzone Has Been Named Chief Financial Officer

Reuters
·
Sep 03, 2025

Lixte Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

THOMSON REUTERS
·
Sep 03, 2025

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

GlobeNewswire
·
Aug 27, 2025